The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of HRS-7085.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
16
Single oral administration
Single oral administration
Linear Clinical Research
Nedlands, Western Australia, Australia
Incidence and severity of adverse events
Time frame: Start of Treatment to end of study approximately 1 week
Pharmacokinetics-AUC0-last
Area under the concentration-time curve from time 0 to last time point after HRS-7085 administration
Time frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-AUC0-inf
Area under the concentration-time curve from time 0 to infinity after HRS-7085 administration
Time frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-Tmax
Time to Cmax of HRS-7085
Time frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-Cmax
Maximum observed concentration of HRS-7085
Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-CL/F
Apparent clearance of HRS-7085
Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-Vz/F
Apparent volume of distribution during terminal phase of HRS-7085
Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)
Pharmacokinetics-t1/2
Terminal elimination half-life of HRS-7085
Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.